# Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept

> **NCT04287348** · PHASE4 · TERMINATED · sponsor: **Vista Klinik** · enrollment: 16 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Brolucizumab 6 mg solution for intravitreal injection

## Key facts

- **NCT ID:** NCT04287348
- **Lead sponsor:** Vista Klinik
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-20
- **Primary completion:** 2021-11-22
- **Final completion:** 2021-11-22
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** due to safety letter beovu from Novartis
- **Last updated:** 2021-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04287348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04287348, "Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04287348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*